Dechra Pharmaceuticals Management
Management criteria checks 4/4
Dechra Pharmaceuticals' CEO is Ian Page, appointed in Nov 2001, has a tenure of 22.17 years. total yearly compensation is £1.04M, comprised of 59.9% salary and 40.1% bonuses, including company stock and options. directly owns 0.36% of the company’s shares, worth $19.79M. The average tenure of the management team and the board of directors is 4.8 years and 4.3 years respectively.
Key information
Ian Page
Chief executive officer
UK£1.0m
Total compensation
| CEO salary percentage | 59.9% |
| CEO tenure | 22.2yrs |
| CEO ownership | 0.4% |
| Management average tenure | 4.8yrs |
| Board average tenure | 4.3yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2023 | UK£1m | UK£621k | -UK£28m |
| Mar 31 2023 | n/a | n/a | UK£6m |
| Dec 31 2022 | n/a | n/a | UK£40m |
| Sep 30 2022 | n/a | n/a | UK£49m |
| Jun 30 2022 | UK£2m | UK£597k | UK£58m |
| Mar 31 2022 | n/a | n/a | UK£66m |
| Dec 31 2021 | n/a | n/a | UK£73m |
| Sep 30 2021 | n/a | n/a | UK£64m |
| Jun 30 2021 | UK£3m | UK£551k | UK£56m |
| Mar 31 2021 | n/a | n/a | UK£50m |
| Dec 31 2020 | n/a | n/a | UK£44m |
| Sep 30 2020 | n/a | n/a | UK£39m |
| Jun 30 2020 | UK£2m | UK£517k | UK£34m |
| Mar 31 2020 | n/a | n/a | UK£31m |
| Dec 31 2019 | n/a | n/a | UK£29m |
| Sep 30 2019 | n/a | n/a | UK£30m |
| Jun 30 2019 | UK£3m | UK£500k | UK£31m |
| Mar 31 2019 | n/a | n/a | UK£28m |
| Dec 31 2018 | n/a | n/a | UK£25m |
| Sep 30 2018 | n/a | n/a | UK£30m |
| Jun 30 2018 | UK£3m | UK£500k | UK£36m |
| Mar 31 2018 | n/a | n/a | UK£40m |
| Dec 31 2017 | n/a | n/a | UK£43m |
| Sep 30 2017 | n/a | n/a | UK£35m |
| Jun 30 2017 | UK£3m | UK£490k | UK£26m |
Compensation vs Market: Ian's total compensation ($USD1.31M) is below average for companies of similar size in the US market ($USD7.67M).
Compensation vs Earnings: Ian's compensation has been consistent with company performance over the past year.
CEO
Ian Page (62 yo)
22.2yrs
Tenure
UK£1,037,000
Compensation
Mr. Ian D. Page has been the Chief Executive Officer and Managing Director of Dechra Pharmaceuticals Plc since November 2001 and 1998 respectively and also serves as its Executive Director since June 13, 1...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, MD & Executive Director | 22.2yrs | UK£1.04m | 0.36% $ 19.8m | |
| CFO & Executive Director | 4.8yrs | UK£641.00k | 0.010% $ 572.9k | |
| Chief Scientific Officer | 1.5yrs | no data | no data | |
| Chief Information Officer | 1.6yrs | no data | no data | |
| Chief People Officer | no data | no data | no data | |
| President of North America | no data | no data | no data | |
| Company Secretary | 6.5yrs | no data | no data |
4.8yrs
Average Tenure
53yo
Average Age
Experienced Management: DPHA.Y's management team is considered experienced (4.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, MD & Executive Director | 26.6yrs | UK£1.04m | 0.36% $ 19.8m | |
| CFO & Executive Director | 4.3yrs | UK£641.00k | 0.010% $ 572.9k | |
| Independent Non-Executive Director | less than a year | UK£36.00k | no data | |
| Senior Independent Director | 7.1yrs | UK£107.00k | 0.0052% $ 287.6k | |
| Independent Non-Executive Chairman | 3.8yrs | UK£207.00k | 0.0033% $ 181.7k | |
| Designated Non-Executive Director | 4.9yrs | UK£72.00k | 0.0012% $ 67.4k | |
| Independent Non-Executive Director | 1.6yrs | UK£73.00k | 0.00053% $ 29.5k |
4.3yrs
Average Tenure
59yo
Average Age
Experienced Board: DPHA.Y's board of directors are considered experienced (4.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/01/16 12:55 |
| End of Day Share Price | 2024/01/16 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2023/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Dechra Pharmaceuticals PLC is covered by 21 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Samuel England | Berenberg |
| Laurent Gelebart | BNP Paribas Exane |
| Brian White | Cantor Fitzgerald Europe |